A Phase 1/2 interventional study of High-activity natural killer in Tongue Cancer, sponsored by Fuda Cancer Hospital, Guangzhou. Completed at 1 site in China. Open to participants aged 30 Years to 60 Years. Per ClinicalTrials.gov, last updated 2019-09-12.
Sponsored by Fuda Cancer Hospital, Guangzhou · Phase 1/2, Interventional, and Treatment
The aim of this study is the safety and efficacy of high-activity natural killer immunotherapy to small metastases of tongue cancer.
By enrolling patients with small metastases of tongue cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of high-activity natural killer cells.
The safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).
85 studies on the registry are indexed under Tongue Neoplasms; 13 are open to participants now.
This study's enrollment of 20 is below the median of 40 across 67 interventional studies indexed under Tongue Neoplasms.
Browse Tongue Neoplasms studies →Fuda Cancer Hospital, Guangzhou is the lead sponsor of 113 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
In this group, the patients will receive multiple high-activity natural killer (HANK) immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
Biological: High-activity natural killer
In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
Each treatment: 8-10 billion cells in all, transfuion in 3 times, i.v.
Relief degree of tumors
It will be evaluated by the Response Evaluation Criteria in Solid Tumors（RECIST）
Time frame: 3 months
Progress free survival（PFS）
Time frame: 1 year
Overall survival（OS）
Time frame: 3 years
This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fuda Cancer Hospital, Guangzhou